GB Patent

GB2383042A — Amorphous alendronate sodium

Assigned to Cipla Ltd · Expires 2003-06-18 · 23y expired

What this patent protects

Amorphous alendronate sodium is a useful form of sodium alendronate for pharmaceutical purposes. It is produced by removing solvent from a solution thereof.

USPTO Abstract

Amorphous alendronate sodium is a useful form of sodium alendronate for pharmaceutical purposes. It is produced by removing solvent from a solution thereof.

Drugs covered by this patent

mitapivat-sulfate (MITAPIVAT SULFATE)

Patent Metadata

Patent number: GB2383042A
Jurisdiction: GB
Classification: —
Expires: 2003-06-18
Drug substance claim: No
Drug product claim: No
Assignee: Cipla Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.